BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 7920315)

  • 1. CMV prophylaxis with foscarnet in allogeneic bone marrow transplant recipients at high risk of developing CMV infections.
    Bacigalupo A; Tedone E; Van Lint MT; Trespi G; Lonngren M; Sanna MA; Moro F; Frassoni F; Occhini D; Gualandi F
    Bone Marrow Transplant; 1994 Jun; 13(6):783-8. PubMed ID: 7920315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Foscarnet prophylaxis of cytomegalovirus infections in patients undergoing allogeneic bone marrow transplantation (BMT): a dose-finding study.
    Bregante S; Bertilson S; Tedone E; Van Lint MT; Trespi G; Mordini N; Berisso G; Gualandi F; Lamparelli T; Figari O; Benvenuto F; Raiola AM; Bacigalupo A
    Bone Marrow Transplant; 2000 Jul; 26(1):23-9. PubMed ID: 10918402
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow transplantation for chronic myeloid leukemia (CML) from unrelated and sibling donors: single center experience.
    Lamparelli T; Van Lint MT; Gualandi F; Occhini D; Barbanti M; Sacchi N; Ficai G; Ghinatti C; Ferrara GB; Delfino L; Pozzi S; Morabito A; Zikos P; Vitale V; Corvo R; Frassoni F; Bacigalupo A
    Bone Marrow Transplant; 1997 Dec; 20(12):1057-62. PubMed ID: 9466278
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV-antigenemia after allogeneic bone marrow transplantation: correlation of CMV-antigen positive cell numbers with transplant-related mortality.
    Bacigalupo A; Tedone E; Isaza A; Soracco M; Van Lint MT; Sanna A; Frassoni F; Occhini D; Gualandi F; Lamparelli T
    Bone Marrow Transplant; 1995 Jul; 16(1):155-61. PubMed ID: 7581116
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
    Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
    Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Foscarnet for prevention of cytomegalovirus infection in allogeneic marrow transplant recipients unable to receive ganciclovir.
    Ippoliti C; Morgan A; Warkentin D; van Besien K; Mehra R; Khouri I; Giralt S; Gajewski J; Champlin R; Andersson B; Przepiorka D
    Bone Marrow Transplant; 1997 Sep; 20(6):491-5. PubMed ID: 9313883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined foscarnet -ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation (Hsct).
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Moro F; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Bone Marrow Transplant; 1996 Nov; 18 Suppl 2():110-4. PubMed ID: 8932810
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Forscarnet vs ganciclovir for cytomegalovirus (CMV) antigenemia after allogeneic hemopoietic stem cell transplantation (HSCT): a randomised study.
    Moretti S; Zikos P; Van Lint MT; Tedone E; Occhini D; Gualandi F; Lamparelli T; Mordini N; Berisso G; Bregante S; Bruno B; Bacigalupo A
    Bone Marrow Transplant; 1998 Jul; 22(2):175-80. PubMed ID: 9707026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot phase II study of alternate day ganciclovir and foscarnet in preventing cytomegalovirus (CMV) infections in at-risk pediatric and adolescent allogeneic stem cell transplant recipients.
    Shereck EB; Cooney E; van de Ven C; Della-Lotta P; Cairo MS
    Pediatr Blood Cancer; 2007 Sep; 49(3):306-12. PubMed ID: 16972242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ganciclovir prophylaxis for cytomegalovirus infection in pediatric allogeneic bone marrow transplant recipients.
    Canpolat C; Culbert S; Gardner M; Whimbey E; Tarrand J; Chan KW
    Bone Marrow Transplant; 1996 Apr; 17(4):589-93. PubMed ID: 8722360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
    Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
    Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of cytomegalovirus antigenemia and shell vial culture in allogeneic marrow transplantation recipients receiving ganciclovir prophylaxis.
    Nicholson VA; Whimbey E; Champlin R; Abi-Said D; Przepiorka D; Tarrand J; Chan K; Bodey GP; Goodrich JM
    Bone Marrow Transplant; 1997 Jan; 19(1):37-41. PubMed ID: 9012929
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival in allogeneic bone marrow transplant recipients following acyclovir prophylaxis for CMV infection. The European Acyclovir for CMV Prophylaxis Study Group.
    Prentice HG; Gluckman E; Powles RL; Ljungman P; Milpied NJ; Camara R; Mandelli F; Kho P; Kennedy L; Bell AR
    Bone Marrow Transplant; 1997 Jan; 19(2):129-33. PubMed ID: 9116609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased incidence of cytomegalovirus (CMV) infection and CMV-associated disease after allogeneic bone marrow transplantation from unrelated donors. The Fukuoka Bone Marrow Transplantation Group.
    Takenaka K; Gondo H; Tanimoto K; Nagafuji K; Fujisaki T; Mizuno S; Miyamoto T; Okamura T; Hayashi S; Eto T; Osaki K; Yamasaki K; Shibuya T; Harada N; Teshima T; Matsuishi E; Minematsu T; Minamishima Y; Harada M; Niho Y
    Bone Marrow Transplant; 1997 Feb; 19(3):241-8. PubMed ID: 9028553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined foscarnet-ganciclovir treatment for cytomegalovirus infections after allogeneic hemopoietic stem cell transplantation.
    Bacigalupo A; Bregante S; Tedone E; Isaza A; Van Lint MT; Trespi G; Occhini D; Gualandi F; Lamparelli T; Marmont AM
    Transplantation; 1996 Aug; 62(3):376-80. PubMed ID: 8779686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Foscarnet for pre-emptive therapy of CMV infection detected by a leukocyte-based nested PCR in allogeneic bone marrow transplant patients.
    Ljungman P; Oberg G; Aschan J; Ehrnst A; Lönnqvist B; Pauksen K; Sulila P
    Bone Marrow Transplant; 1996 Sep; 18(3):565-8. PubMed ID: 8879618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced risk of persisting cytomegalovirus pp65 antigenemia and cytomegalovirus interstitial pneumonia following allogeneic PBSCT.
    Trenschel R; Ross S; Hüsing J; Ottinger H; Elmaagacli A; Roggendorf M; Schaefer UW; Runde V
    Bone Marrow Transplant; 2000 Mar; 25(6):665-72. PubMed ID: 10734302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised trial comparing cytomegalovirus antigenemia assay vs screening bronchoscopy for the early detection and prevention of disease in allogeneic bone marrow and peripheral blood stem cell transplant recipients.
    Humar A; Lipton J; Welsh S; Moussa G; Messner H; Mazzulli T
    Bone Marrow Transplant; 2001 Sep; 28(5):485-90. PubMed ID: 11593322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early reactivation of cytomegalovirus and high risk of interstitial pneumonitis following T-depleted BMT for adults with hematological malignancies.
    Couriel D; Canosa J; Engler H; Collins A; Dunbar C; Barrett AJ
    Bone Marrow Transplant; 1996 Aug; 18(2):347-53. PubMed ID: 8864445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.